[go: up one dir, main page]

WO2019225754A1 - Déodorant et inactivateur - Google Patents

Déodorant et inactivateur Download PDF

Info

Publication number
WO2019225754A1
WO2019225754A1 PCT/JP2019/020759 JP2019020759W WO2019225754A1 WO 2019225754 A1 WO2019225754 A1 WO 2019225754A1 JP 2019020759 W JP2019020759 W JP 2019020759W WO 2019225754 A1 WO2019225754 A1 WO 2019225754A1
Authority
WO
WIPO (PCT)
Prior art keywords
tension
odor
oil
deodorant
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2019/020759
Other languages
English (en)
Japanese (ja)
Inventor
勇太 間中
山田　俊一
薫 森下
雅子 勝山
落合　正敏
明宏 瓦谷
裕香理 桑原
貴大 石川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takasago International Corp
Shiseido Co Ltd
Original Assignee
Takasago International Corp
Shiseido Co Ltd
Takasago Perfumery Industry Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takasago International Corp, Shiseido Co Ltd, Takasago Perfumery Industry Co filed Critical Takasago International Corp
Priority to CN201980035382.2A priority Critical patent/CN112135602B/zh
Priority to JP2020520403A priority patent/JPWO2019225754A1/ja
Publication of WO2019225754A1 publication Critical patent/WO2019225754A1/fr
Anticipated expiration legal-status Critical
Priority to JP2023181781A priority patent/JP2024020230A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q13/00—Formulations or additives for perfume preparations
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B9/00—Essential oils; Perfumes

Definitions

  • This disclosure relates to a deodorant that eliminates or reduces discomfort caused by body odor.
  • the present disclosure relates to an inactivating agent that inactivates a physiological / psychological activity (modulation) action by a secretory component from a human body.
  • aging odor is known as a body odor peculiar to middle-aged and elderly people (see, for example, Patent Document 1).
  • the aging odor suppressing fragrance composition described in Patent Document 1 has a component excellent in the masking effect on the aging odor and / or a component excellent in the harmony effect on the aging odor. It is blended.
  • Patent Document 2 discloses at least one selected from the group consisting of butyl 2-methylbutanoate, ⁇ -terpinene, dipentene, cis-4-heptenal, 1,4-cineole, trimethylhexylaldehyde, and (+)-limonene oxide.
  • An inhibitor of the odor of a polysulfide compound is disclosed which contains as an active ingredient.
  • the present inventors have noticed that there is a peculiar smell around a person who is in a tension state (stress state) in which the heart rate increases due to mental stress. Therefore, the present inventors have studied the cause of the odor.
  • the odor is a body odor caused by a substance secreted / released from a person in a tension state or a mental stress state (hereinafter referred to as “tension” in this disclosure). Odor "or” stress odor ").
  • This tension odor is a sulfur-based odor that many people will feel uncomfortable.
  • interest in body odor has increased, and it is expected that demand for deodorants that can eliminate or reduce discomfort caused by tension odor will increase.
  • the odor suppressor described in Patent Document 2 refers only to bad odors other than the human body such as drain outlets and garbage, and has not been studied for bad odors emitted from the human body, and the odor described in Patent Document 2 It is unclear whether the suppressor can suppress the tension odor.
  • a component secreted and released from a person who is in a tension state or mental stress state has at least one of a physiologically active action and a psychologically active action. thinking. Therefore, inactivity that inactivates physiological activity and / or psychological activity by a component secreted from a person in tension and / or mental stress (hereinafter referred to as “tension odor component”). It is expected that demand for the agent will increase.
  • the inactivating agent of the present disclosure it is possible to inactivate or suppress the psychological or physiological activity action by the tension odor component.
  • Example 10 is a graph showing the results in Example 5.
  • the tension odor deodorant contains at least one of the above components ⁇ 1> to ⁇ 34> and combinations thereof as a masking agent for the tension odor.
  • the tension odor deodorant contains at least one of the above components ⁇ 1> to ⁇ 22> and combinations thereof as a harmonizing agent for the tension odor.
  • the strained deodorant contains at least one of the above components ⁇ 1> to ⁇ 22> and combinations thereof as a masking agent and a harmonicizing agent for the strained odor. .
  • the tension odor is an odor emitted from the body due to a tension state and / or mental stress.
  • the causative substance of the tension odor includes at least one of allyl mercaptan and dimethyl trisulfide.
  • the causative substance further contains at least one of dimethyl disulfide and methylpropyl trisulfide.
  • the causative substance further includes 1-octen-3-one.
  • the secretory component is a component secreted from the body due to tension and / or mental stress.
  • the secretory component contains at least one of allyl mercaptan and dimethyl trisulfide.
  • the secretory component further contains at least one of dimethyl disulfide and methylpropyl trisulfide.
  • the secretory component further contains 1-octen-3-one.
  • the deodorant of the present disclosure is a deodorant that can be suitably applied to body odor (tension odor) emitted when a person is in a tension state and / or a mental stress state.
  • the deodorization referred to in the present disclosure is to prevent or mitigate a odor to be deodorized (hereinafter referred to as “bad odor”) by a sensory action.
  • a masking action masking effect
  • a harmonizing action can be considered.
  • masking refers to competing with a good scent (aroma, fragrance) superior to the bad odor against the bad odor and relatively deodorizing (removing or mitigating the bad odor).
  • harmonization refers to deodorizing odors by mixing odors that harmonize with bad odors and harmonizing odors as a whole (for example, converting bad odors into fragrances and fragrances). To resolve or alleviate).
  • the deodorizer of the present disclosure includes at least one of the following components as the first deodorant component: ⁇ 1> Spearmint oil; ⁇ 2> Lavandin oil; ⁇ 3> Brackish oil (peppermint oil); ⁇ 4>l-citronellal; ⁇ 5>linalool; ⁇ 6> dihydromyrcenol (2,6- ⁇ 7>cis-3-hexenol; ⁇ 8> Tripral (dimethyl-3-cyclohexene-1-carbaldehyde); ⁇ 9> benzyl acetate; ⁇ 10> rosmarin oil (rose) ⁇ 11> cis-3-hexenyl acetate; ⁇ 12> lavender oil; ⁇ 13> (R) -3,7-dimethyl-6-octenenitrile (commercially available products include, for example, LEVOCITRIE (registered trademark: Takasago International Corporation)); ⁇ 14> (1R, 6S) -2,2,6-trimethyl-
  • the deodorant of the present disclosure preferably contains at least one selected from the group consisting of the above components ⁇ 1> to ⁇ 37> and combinations thereof as a masking agent.
  • the deodorant of the present disclosure is a masking agent, from the viewpoint of masking effect, the above components ⁇ 1> to ⁇ 24>, ⁇ 26>, ⁇ 27>, ⁇ 31>, and ⁇ 35> to ⁇ 37>, And at least one component selected from the group consisting of these combinations, and at least one component selected from the group consisting of the above components ⁇ 1> to ⁇ 6> and ⁇ 35> and combinations thereof It is more preferable that it contains.
  • the deodorant of the present disclosure preferably contains at least one selected from the group consisting of the above components ⁇ 1> to ⁇ 22> and ⁇ 35> to ⁇ 37> and combinations thereof as a harmonizing agent.
  • the deodorant of the present disclosure is a harmonizing agent, from the viewpoint of the harmonizing effect, the components ⁇ 1> to ⁇ 19>, ⁇ 35> to ⁇ 37>, and combinations thereof are used. More preferably, it includes at least one selected component, and more preferably includes at least one component selected from the group consisting of the above components ⁇ 1> to ⁇ 18> and combinations thereof.
  • the deodorizer of the present disclosure can be used in combination with a masking action and a harmonicizing action. That is, the deodorizer of this indication can contain a masking agent and a harmonizing agent.
  • the components ⁇ 1> to ⁇ 22> and ⁇ 35> to ⁇ 37>, and combinations thereof, have both a masking action and a harmonizing action, so that the tension odor can be effectively deodorized. .
  • the deodorant of the present disclosure can be sprayed in the air in advance and / or after the event in a place where a tension odor is generated and / or a place where the tension odor may be generated.
  • the deodorant can be attached to or spread on fabric products such as clothes, curtains and carpets in advance and / or after the fact. If the deodorant does not adversely affect the skin, the deodorant can be applied to the skin in advance and / or after the fact.
  • a deodorant can be applied to a place where a tension odor component is considered to be secreted, for example, palm, armpit, foot, back, head, face, oral cavity, and the like.
  • the deodorant of the present disclosure can be used in combination with other deodorants, those that remove or mitigate bad odors by chemical, biological, physical action and the like.
  • the deodorant of the present disclosure can further contain a deodorizing component, a deodorizing component, another deodorizing component, and the like as long as the effect of the deodorant of the present disclosure is not impaired.
  • the deodorant of the present disclosure can eliminate or alleviate discomfort that occurs when smelling a tension odor.
  • a person who is or has been in a tension state or mental stress state, or a person who is likely to become a tension state or mental stress state in the future generates a tension odor by using the deodorant of the present disclosure.
  • the anxiety that it may be present and the anxiety that it may generate a tense odor can be eliminated or reduced in advance and / or after the fact.
  • the deodorant according to the second embodiment may further contain a second deodorant component that physically and chemically deodorizes (deodorizes) the tension odor in addition to the deodorant according to the first embodiment.
  • the second deodorizing component refers to a component that removes or mitigates (deodorizes) the bad odor by a chemical action and / or a physical action on the causative substance of the bad odor.
  • the components listed in the present disclosure remove or mitigate malodors other than by chemical action and / or physical action, they do not fall outside the scope of the deodorant of the present disclosure.
  • the second deodorant component includes at least one of the first deodorant component and the second deodorant component.
  • the first deodorizing component can include at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, Kamsnar extract, Lumpuyan extract, and combinations thereof.
  • the first deodorant component is considered to be useful for deodorizing malodor caused by allyl mercaptan among causative substances of tension odor.
  • the silver-supported zeolite includes, for example, one in which at least a part of ion-exchangeable ions in the zeolite is replaced with silver ions.
  • the silver ion content in the silver-supported zeolite can be, for example, 0.1% by mass to 15% by mass.
  • the second deodorant component is laponite, silver supported zeolite, zinc oxide, neem leaf extract, iris leaf extract, perilla leaf extract, hydroxypropyl- ⁇ -cyclodextrin, sanna extract, tocopherol, dibutylhydroxytoluene, sugarcane extract, loquat leaf It may comprise at least one selected from the second group consisting of extracts, green tea extracts, and combinations thereof.
  • the second deodorizing component is considered to be useful for deodorizing malodor caused by dimethyl trisulfide, among substances causing tension odor.
  • the second deodorant component is (A) zinc oxide and (B) laponite, silver-supported zeolite, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl- ⁇ -cyclodextrin , Sanna extract, green tea extract, and at least one selected from the third group consisting of combinations thereof. According to this combination, the deodorizing effect of the tension odor can be further enhanced.
  • Zinc oxide can be fine powder.
  • the average particle diameter of zinc oxide can be, for example, 5 ⁇ m or less, 3 ⁇ m or less, 2 ⁇ m or less, 1 ⁇ m or less, or 0.5 ⁇ m or less.
  • the main components of the causative substance of the tension odor are allyl mercaptan and dimethyl trisulfide, as will be described later. Both substances have a particularly large impact on the sense of smell. Therefore, if the odors of allyl mercaptan and dimethyl trisulfide are eliminated, the tension odor can be effectively eliminated.
  • the second deodorizing component has a deodorizing effect on the tension odor. From this, according to the deodorizer which concerns on 2nd Embodiment, the deodorizing effect of a tension odor can further be heightened by combining a 1st deodorizing component and a 2nd deodorizing component.
  • a deactivation agent according to the third embodiment of the present disclosure will be described.
  • the tension odor component has at least one of a psychological activity and a physiological activity on humans. For example, when a person senses a tense odor, or when an olfactory receptor responds to a tense odor component, it becomes clear that the person is mentally fatigued, confused, or awakened. It's getting on.
  • the tension odor component may have a psychoactive activity and / or psychological activity other than these.
  • the inactivating agent of the present disclosure has an effect of inactivating such a mental activity and / or psychological activity of the tension odor component.
  • the person when a person senses the scent of the inactivation agent of the present disclosure, mixes and smells the scent of the inactivation agent and a tension odor, or when the olfactory receptor responds to the inactivation agent, etc.
  • the person can eliminate or suppress the mental modulation and / or psychological modulation as described above.
  • Negative emotions include, for example, “anger / hostility”, “confused / embarrassed”, “depressed / depressed”, “fatigue / impotence”, and “tension / impotence” based on the POMS (Profile of Mood States) test. Anxiety ”is mentioned. It has been found that the tension odor particularly increases “confused / embarrassed”, “fatigue / apathy” and “tension / anxiety”. Positive emotions include, for example, “liveliness / energy” and “friendship”.
  • the inactive agent of the present disclosure includes at least one of the following components as a first inactivating component: ⁇ 1> Spearmint oil; ⁇ 2> Lavandin oil; ⁇ 3> Brackish oil; ⁇ 4>1-citronellal; ⁇ 5>Linalool; ⁇ 6> Dihydromyrsenol (2,6-dimethyl-7- (7) cis-3-hexenol; ⁇ 8> tripral (dimethyl-3-cyclohexene-1-carbaldehyde); ⁇ 9> benzyl acetate; ⁇ 10> rosmarin oil (rosemary oil); ⁇ 11> cis-3-hexenyl acetate; ⁇ 12> lavender oil; ⁇ 13> (R) -3,7-dimethyl-6-octenenitrile (for example, LEVOCITRILE (registered trademark: Takasago International Corporation) ⁇ 14> (1R, 6S) -2,2,6-trimethyl-cyclohex
  • Ethyl 2-tricyclo [5.2.1.02,6] decan-2-ylcarboxylate (commercially available products include, for example, FRUITATE (registered trademark: Kao).
  • FRUITATE registered trademark: Kao
  • the inactivating agent and inactivating action of the present disclosure it is preferable to include at least one selected from the group consisting of the above components ⁇ 1> to ⁇ 37> and combinations thereof, and the above component ⁇ 1> More preferably, it includes at least one component selected from the group consisting of ⁇ 24>, ⁇ 26>, ⁇ 27>, ⁇ 31>, and ⁇ 35> to ⁇ 37>, and combinations thereof. More preferably, it includes at least one component selected from the group consisting of 1> to ⁇ 6> and ⁇ 35>, and combinations thereof.
  • Psychologically active and physiologically active effects due to the tension odor component, and inactivation of the tension odor component due to the inactive agent are, for example, a method using a psychological questionnaire such as POMS (registered trademark) (Profile of Mood States). ), GACL (General Activity Checklist) or the like.
  • POMS registered trademark
  • GACL General Activity Checklist
  • the inactivating agent of the present disclosure can be sprayed in the air in advance and / or after the event in a place where a tension odor component is generated and / or a place where it may be generated.
  • the deactivator can also be applied or spread on fabric products such as clothes, curtains and carpets in advance and / or after the fact. If the deactivator does not adversely affect the skin, the deactivator can be applied to the skin in advance and / or after the fact.
  • a deodorant can be applied to a place where a tension odor component is considered to be secreted, for example, palm, armpit, foot, back, head, face, oral cavity, and the like.
  • the inactivating agent of the present disclosure can be used in combination with other psychological and physiological action inactivating agents and the like.
  • the inactivation agent of the present disclosure may further contain another inactivation agent as long as the effect of the inactivation agent of the present disclosure is not inhibited.
  • Other deactivators include, for example, those that remove or mitigate malodors by chemical, biological, physical action, etc. against malodors (eg, tension odors) (eg, deodorant components, deodorant components, deodorant components) Etc.).
  • the inactivating agent of the present disclosure can inactivate the mental activity and / or psychological activity of the tension odor component. Thereby, psychological modulation, physiological modulation, and the like caused by the tension odor component can be eliminated or suppressed. Persons who are or have been in tension or mental stress, or who are likely to become tension or mental stress, in advance and / or after using the inactivating agent of the present disclosure It is possible to take measures such as psychological modulation and physiological modulation.
  • the deactivating agent according to the fourth embodiment further includes at least one of the second deactivating component and the third deactivating component in addition to the deactivating agent according to the third embodiment.
  • the second deactivating component can include at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, Kamsnar extract, Lumpuyan extract, and combinations thereof.
  • the first inactivating component is considered to be useful for inactivating malodor caused by allyl mercaptan among causative substances of tension odor.
  • the third inactivating component is laponite, silver supported zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, hydroxypropyl- ⁇ -cyclodextrin, sanna extract, tocopherol, dibutylhydroxytoluene, sugarcane extract, loquat At least one selected from the second group consisting of leaf extract, green tea extract, and combinations thereof may be included.
  • the second inactivating component is considered to be useful for inactivating malodor caused by dimethyl trisulfide, among the causative substances of tension odor.
  • the third inactivating component is (A) zinc oxide, (B) laponite, silver-supported zeolite, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl- ⁇ -cyclo
  • Zinc oxide can be fine powder.
  • the average particle diameter of zinc oxide can be, for example, 5 ⁇ m or less, 3 ⁇ m or less, 2 ⁇ m or less, 1 ⁇ m or less, or 0.5 ⁇ m or less.
  • the main components of the causative substance of the tension odor are allyl mercaptan and dimethyl trisulfide, as will be described later. Both substances have a particularly large impact on the sense of smell. Therefore, if the odors of allyl mercaptan and dimethyl trisulfide are eliminated, the psychological and / or physiologically active action due to the tension odor can be effectively inactivated.
  • the deactivating agent according to the fourth embodiment contains a second deactivating component and / or a third deactivating component having an action different from that of the first deactivating component. It is possible to further inactivate the mental activity and / or the psychological activity by the component.
  • the method for producing the deodorant and the deactivator of the present disclosure is not particularly limited.
  • a deodorant and an inactivating agent can be produced by mixing deodorant components.
  • ⁇ Tension odor is an odor emitted from the body when nervous or under stress.
  • the tension or mental stress here includes, for example, tension or stress that depends on interpersonal relationships.
  • Interpersonal tension / stress is, for example, the tension / stress that is being announced in public (especially before a large number of people), the tension / stress that is undergoing an important or oppressive interview Etc.
  • the heart rate per minute is 20 bpm (beats per minute) or more, preferably 30 bpm or more higher than that at normal rest. It can be said that it is in a state.
  • Normal resting means resting without mental stress and a state in which heart rate does not fluctuate, for example, a state of sitting and relaxing for a predetermined time or longer.
  • the tension odor is considered to be based on the components contained in the blood.
  • “generation from the body (secretion / release)” means generation (secretion / release) from the skin, mucous membrane and / or oral cavity.
  • “Body odor” in the present disclosure includes bad breath.
  • the tension odor component includes a compound containing sulfur element (sulfur compound).
  • sulfur compound examples include at least one of allyl mercaptan and dimethyl trisulfide.
  • the tension odor component includes both allyl mercaptan and dimethyl trisulfide.
  • the allyl mercaptan can be 0.1 ppb or more, 0.3 ppb or more, 0.5 ppb or more, 1 ppb or more, or 10 ppb or more on a volume basis.
  • the allyl mercaptan can be 1,000 ppm or less, 100 ppm or less, 10 ppm or less, 1 ppm or less, 500 ppb or less, 100 ppb or less, or 10 ppb or less on a volume basis.
  • Dimethyl trisulfide can be 1 ppb or more, 2 ppb or more, 3 ppb or more, 5 ppb or more, 10 ppb or more, 20 ppb or more, 50 ppb or more, or 100 ppb or more on a volume basis.
  • Dimethyl trisulfide can be 10,000 ppm or less, 1,000 ppm or less, 100 ppm or less, 10 ppm or less, 1 ppm or less, 100 ppb or less, or 10 ppb or less on a volume basis.
  • the mass ratio of allyl mercaptan to dimethyl trisulfide is, for example, 2 parts by mass or more, 5 parts by mass or more, 10 parts by mass or more, or 15 parts by mass with respect to 1 part by mass of allyl mercaptan. Part or more.
  • the mass ratio of allyl mercaptan and dimethyl trisulfide is, for example, 50 parts by mass or less, 40 parts by mass or less, 30 parts by mass or less, or 25 parts by mass or less with respect to 1 part by mass of allyl mercaptan. Can do.
  • Tension odor components include hydrogen sulfide, methyl mercaptan, carbon disulfide, dimethyl sulfide, dimethyl disulfide, methylpropyl trisulfide, and these as sulfur compounds other than allyl mercaptan and dimethyl trisulfide (hereinafter referred to as “other sulfur compounds”). It may further contain at least one compound selected from the group consisting of:
  • the total amount of sulfur compounds can be 0.1 ppb or more, 1 ppb or more, or 10 ppb or more on a volume basis.
  • the total amount of sulfur compounds can be 10,000 ppm or less, or 1,000 ppm or less on a volume basis.
  • the tension odor component can contain 1-octen-3-one as a non-sulfur compound in addition to or alone with respect to the sulfur compound.
  • 1-octen-3-one can be, for example, 0.1 ppb or more, 0.5 ppb or more, 1 ppb or more, 10 ppb or more, 100 ppb or more, or 1 ppm or more on a volume basis.
  • 1-octen-3-one can be, for example, 1,000 ppm or less, 100 ppm or less, 10 ppm or less, or 1 ppm or less on a volume basis.
  • deodorant and deactivator of the present disclosure will be described below with examples. However, the deodorant and the deactivator of the present disclosure are not limited to the following examples.
  • Example 1 Masking test and Harmonizing test
  • the tension odor component shown in Table 1 was dissolved in medium chain fatty acid to prepare a medium chain fatty acid solution of tension odor.
  • 10 ⁇ L of the deodorant (deactivator) shown in Table 2 and Table 3 is blended as a first deodorant component (first inactivating component) in 100 ⁇ L of this tension odor medium chain fatty acid solution,
  • a test solution of deodorant was prepared.
  • each test solution was impregnated into a 2 cm square filter paper.
  • the filter paper was put into a disposable beaker having a capacity of 500 mL, and the beaker was sealed with aluminum foil. 30 minutes after sealing, a hole having a diameter of about 1 cm was formed in the aluminum foil.
  • Tables 2 and 3 show the average evaluation scores of 17 expert panels.
  • the deodorizers of Test Examples 1 to 37 had a masking effect score of 1.5 or more, and were found to be effective in mitigating the tension odor.
  • a deodorant having a score of 2 or more, preferably 2.5 or more has a high masking effect against a tension odor.
  • the deodorizers of Test Examples 1 to 22 and 35 to 37 had a score of 0.5 or more with respect to the harmonizing effect, and were found to be effective in reducing discomfort due to a tension odor.
  • a deodorant having a score of 0.6 or more, preferably 0.7 or more has a high harmonizing effect against the tension odor.
  • the deodorizers of Test Examples 1 to 22 and 35 to 37 have both a masking effect and a harmonizing effect. Therefore, the deodorizers of Test Examples 1 to 22 and 35 to 37 could remarkably reduce discomfort due to the tension odor or eliminate the tension odor due to both effects.
  • a deodorant having a masking effect score of 2.5 or more and a harmony effect score of 0.6 or more was useful for deodorizing tension odors.
  • Example 2 Deodorization test for dimethyl trisulfide
  • Deodorant solution 0.05% by mass and dipropylene glycol 99.95% by mass are mixed as a second deodorant component (second inactivation component), and a deodorant solution is prepared for each deodorant.
  • 1 mL of the deodorant solution and 5 ⁇ 10 ⁇ 4 parts by mass of dimethyl trisulfide with respect to 1 part by mass of the deodorant were injected into a sample tube having a capacity of 30 mL.
  • Three expert panels sniffed the scent in the sample tube and evaluated the deodorizing effect of each deodorant on dimethyltrisulfide according to the following criteria.
  • Table 4 shows the deodorant tested and the evaluation of the deodorizing effect of each deodorant by a specialized panel.
  • the evaluation shown in Table 4 represents the average score of the specialized panel according to the following criteria.
  • the average particle size of zinc oxide used in the following examples is about 0.2 ⁇ m.
  • A 2 points; B: 1.5 points or more and less than 2 points; C: 1 point or more and less than 1.5 point; D: Less than 1 point.
  • the deodorizers of Test Examples 51 to 55 were confirmed to have a deodorizing effect on dimethyl trisulfide, which is a causative substance of tension odor. Therefore, the deodorizers of Test Examples 51 to 55 are considered effective for deodorizing tension odors.
  • Example 3 Deodorization test for allyl mercaptan
  • Deodorant as a second deodorant component (second inactivating component) 0.10% by mass and dipropylene glycol 99.90% by mass are mixed, and a deodorant solution is added to each deodorant.
  • 1 mL of the deodorant solution and 5 ⁇ 10 ⁇ 6 parts by mass of allyl mercaptan with respect to 1 part by mass of the deodorant were injected into a 30 mL sample tube.
  • Three expert panels sniffed the scent in the sample tube, and evaluated the deodorizing effect of each deodorant on allyl mercaptan according to the following criteria.
  • Table 5 shows the deodorant tested, and the evaluation of the deodorizing effect by a specialized panel for each deodorant. The evaluation criteria are the same as in Example 2.
  • the deodorizers of Test Examples 60 to 68 were confirmed to have a deodorizing effect on allyl mercaptan, which is a causative substance of tension odor. Therefore, the deodorizers of Test Examples 60 to 68 are considered to be effective for deodorizing tension odors.
  • Example 4 Deodorization test for allyl mercaptan
  • Deodorant as a second deodorant component (second inactivating component) 0.10% by mass and dipropylene glycol 99.90% by mass are mixed, and a deodorant solution is added to each deodorant.
  • the deodorizer contains 50% by mass of zinc oxide as component A and 50% by mass of component B shown in Table 3. 1 mL of the deodorant solution and 2.5 ⁇ 10 ⁇ 6 parts by mass of allyl mercaptan with respect to 1 part by mass of the deodorant were injected into a 30 mL sample tube.
  • Table 6 shows the deodorant tested, and the evaluation of the deodorizing effect by a specialized panel for each deodorant.
  • the evaluation criteria are the same as in Example 2.
  • the deodorizing effect was generally improved as compared with using the deodorant component alone.
  • the test examples 60, 66, 72, 73, and 75 shown in Table 2 are compared with the test examples 76, 82, 87, 88, and 90 shown in Table 3, respectively, the deodorization used in Example 2 is compared.
  • the deodorizing effect could be enhanced compared to the deodorant alone.
  • laponite, hydroxypropyl- ⁇ -dextrin, sugarcane extract, loquat leaf extract, and green tea extract alone had a low deodorizing effect, but the deodorizing effect could be enhanced by mixing with zinc oxide.
  • these deodorizing components and zinc oxide are considered to have a synergistic effect of deodorization. From this, it is thought that mixing of a plurality of types of deodorizing components is more effective for deodorizing tension odors.
  • a deodorant containing zinc oxide as the second deodorant component is considered to be more effective for deodorizing tension odors.
  • the deodorizing effect could be enhanced by increasing the amount of zinc oxide with respect to the malodor-causing substance. From this, if the application amount of a deodorizer is increased with respect to a tension odor, the deodorizing effect can be improved more.
  • Example 5 Psychological / mental effect test
  • the subject was sniffed with a tension odor model composition, and the psychological and mental changes of the subject due to the tension odor were confirmed using POMS (registered trademark) and GACL. As a result, it was confirmed that when the subject smells a tense odor, arousal, fatigue and confusion occur.
  • “Inspection 3” was performed on a different day from Inspection 1 and Inspection 2.
  • the examination 3 first, the subject who carried out the examination 1 and the examination 2 was in a resting state for 20 minutes in the same manner as the examination 1.
  • each subject continued to sniff a sample gas in which 10 ⁇ L of a deodorant having the composition shown in Table 8 was mixed with 100 ⁇ L of the tension odor model composition used in Test 2, for 5 minutes. After that, he asked me to answer the same question as in Exam 1.
  • each component of the tension odor model composition was detected. From this, it is considered that the negative emotion caused by the tension odor in Test 3 did not increase because the subject did not perceive or recognize the tension odor with the deodorant of the present disclosure. From this, it was found that even if a tension odor exists, if the tension odor can be deodorized by the masking action and / or the harmonizing action, the psychological and mental effects caused by the tension odor can be inactivated. That is, it was found that the deodorant of the present disclosure can be applied as an inactivating agent for psychological and mental effects caused by a tension odor.
  • the first deodorizing component includes at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, Camsnar extract, Lumpuyan extract, and combinations thereof;
  • the second deodorant component is composed of laponite, silver supported zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, hydroxypropyl- ⁇ -cyclodextrin, sanna extract, tocopherol, and combinations thereof.
  • a tension odor deodorant comprising at least one selected from the group of:
  • the first deodorizing component includes at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, Camsnar extract, Lumpuyan extract, and combinations thereof;
  • the second deodorant component is Zinc oxide, Selected from the third group consisting of laponite, silver supported zeolite, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl- ⁇ -cyclodextrin, sanna extract, green tea extract, and combinations thereof A deodorant with tension.
  • the first deactivating component includes at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, Kamsnar extract, Lumpuyan extract, and combinations thereof;
  • the second inactivating component includes laponite, silver-supported zeolite, zinc oxide, neem leaf extract, iris root extract, perilla leaf extract, hydroxypropyl- ⁇ -cyclodextrin, sanna extract, tocopherol, and combinations thereof.
  • An inactivating agent that inactivates the psychological or mental activity of secretory components.
  • the first deactivating component is at least one selected from the first group consisting of silver-supported zeolite, tocopherol, zinc oxide, Kamsnar extract, Lumpuyan extract, and combinations thereof;
  • the second inactivating component is Zinc oxide, Selected from the third group consisting of laponite, silver supported zeolite, dibutylhydroxytoluene, sugarcane extract, loquat leaf extract, iris root extract, perilla leaf extract, hydroxypropyl- ⁇ -cyclodextrin, sanna extract, green tea extract, and combinations thereof At least one of An inactivating agent that inactivates the psychological or mental activity of secretory components.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Disinfection, Sterilisation Or Deodorisation Of Air (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Déodorant et inactivateur contenant chacun au moins un ingrédient choisi parmi l'huile de menthe verte, l'huile de lavandin, l'huile de menthe poivrée, le l-citronellal, le linalol, le dihydromyrcénol, le cis-3-hexénol, le triplal, l'acétate de benzyle, l'huile de romarin, l'acétate de cis-3-hexcenyle, l'huile de lavande, le (R)-3,7-diméthyl-6-octénenitrile, l'ester éthylique de l'acide (1R,6S)-2,2,6-triméthylcyclohexanecarboxylique, l'huile d'eucalyptus, la γ-undécalactone, l'huile de rose, le (R)-2-méthyl-4-(2,2,3-triméthyl-3-cyclopenten-1-yl)-2-butén-1-ol, l'(-)-isopulégol, etc.
PCT/JP2019/020759 2018-05-25 2019-05-24 Déodorant et inactivateur Ceased WO2019225754A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201980035382.2A CN112135602B (zh) 2018-05-25 2019-05-24 防臭剂和钝化剂
JP2020520403A JPWO2019225754A1 (ja) 2018-05-25 2019-05-24 防臭剤及び不活性化剤
JP2023181781A JP2024020230A (ja) 2018-05-25 2023-10-23 不活性化剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018100598 2018-05-25
JP2018-100598 2018-05-25

Publications (1)

Publication Number Publication Date
WO2019225754A1 true WO2019225754A1 (fr) 2019-11-28

Family

ID=68615568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/020759 Ceased WO2019225754A1 (fr) 2018-05-25 2019-05-24 Déodorant et inactivateur

Country Status (4)

Country Link
JP (2) JPWO2019225754A1 (fr)
CN (1) CN112135602B (fr)
TW (1) TW202002938A (fr)
WO (1) WO2019225754A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023079982A1 (fr) * 2021-11-05 2023-05-11 株式会社 資生堂 Produit cosmétique de protection solaire

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62212316A (ja) * 1986-03-13 1987-09-18 Agency Of Ind Science & Technol 粉末消臭剤
JP2003506469A (ja) * 1999-08-16 2003-02-18 ピーキュー ホールディング， インコーポレイテッド タマネギまたはニンニクの口臭を減少させるための硫黄吸着剤
JP2004262900A (ja) * 2003-03-04 2004-09-24 Takasago Internatl Corp 体臭抑制香料組成物
JP2005314283A (ja) * 2004-04-28 2005-11-10 Nivea Kao Kk 非水系粉末エアゾール
JP2005350354A (ja) * 2003-09-09 2005-12-22 Kao Corp 腋臭の消臭用組成物、それを含む皮膚化粧料及び繊維用消臭剤
JP2012158768A (ja) * 2012-05-14 2012-08-23 Kao Corp 香料組成物
JP2017020003A (ja) * 2003-07-07 2017-01-26 ジボダン エス エー フレグランス組成物
JP2018052892A (ja) * 2016-09-30 2018-04-05 アース製薬株式会社 スプレー型芳香剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0826956A (ja) * 1994-07-19 1996-01-30 Shinagawa Fuel Co Ltd 防臭化粧料
US5559271A (en) * 1995-07-26 1996-09-24 Phillips Petroleum Company Organic polysulfide compositions having reduced odor
JP2002327193A (ja) * 2001-04-27 2002-11-15 Kiyomitsu Kawasaki 調合香料および該調合香料を含有する洗浄・柔軟剤組成物
JP4582965B2 (ja) * 2001-06-21 2010-11-17 小川香料株式会社 香味料組成物
JP2003027084A (ja) * 2001-07-23 2003-01-29 Kiyomitsu Kawasaki 漂白剤用消臭・芳香組成物
JP2003113392A (ja) * 2001-10-04 2003-04-18 Kiyomitsu Kawasaki 芳香・消臭組成物および該芳香・消臭組成物を含有する人体用芳香・消臭剤
US7763238B2 (en) * 2002-01-16 2010-07-27 Monell Chemical Senses Center Olfactory adaptation and cross-adapting agents to reduce the perception of body odors
JP2004018470A (ja) * 2002-06-18 2004-01-22 Takasago Internatl Corp 抗菌香料組成物および口臭抑制香料組成物ならびにそれらを含有する口腔用組成物
CN101579292A (zh) * 2002-08-09 2009-11-18 花王株式会社 香料组合物
US8961946B2 (en) * 2004-12-20 2015-02-24 Showa Denko K.K. Hair processing agent and method for permanent waving hair
JP2006248921A (ja) * 2005-03-08 2006-09-21 Nivea Kao Kk 発汗抑制剤
US9351944B1 (en) * 2008-11-07 2016-05-31 Takasago International Corporation Malodor eliminating compositions
US8623340B2 (en) * 2009-04-28 2014-01-07 Symrise Ag Omega-cyclohexylalkan-1-oles and use thereof as antimicrobial actives to combat body odor
FR2948661B1 (fr) * 2009-07-31 2011-07-29 Arkema France Composition a base de sulfure organique a odeur masquee
JP5692844B2 (ja) * 2010-09-24 2015-04-01 高砂香料工業株式会社 スルフィド類用消臭剤組成物
TW201347796A (zh) * 2012-05-16 2013-12-01 Meter Nano Technology Company 抗菌除臭劑
WO2015098733A1 (fr) * 2013-12-25 2015-07-02 出光興産株式会社 Zéolite porteuse de métal pour boissons alcoolisées et procédé de fabrication de boissons alcoolisées
JP6342382B2 (ja) * 2015-12-25 2018-06-13 リリース科学工業株式会社 消臭剤
JP6605681B1 (ja) * 2018-10-12 2019-11-13 リリース科学工業株式会社 ピーナッツ渋皮抽出物を得る方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62212316A (ja) * 1986-03-13 1987-09-18 Agency Of Ind Science & Technol 粉末消臭剤
JP2003506469A (ja) * 1999-08-16 2003-02-18 ピーキュー ホールディング， インコーポレイテッド タマネギまたはニンニクの口臭を減少させるための硫黄吸着剤
JP2004262900A (ja) * 2003-03-04 2004-09-24 Takasago Internatl Corp 体臭抑制香料組成物
JP2017020003A (ja) * 2003-07-07 2017-01-26 ジボダン エス エー フレグランス組成物
JP2005350354A (ja) * 2003-09-09 2005-12-22 Kao Corp 腋臭の消臭用組成物、それを含む皮膚化粧料及び繊維用消臭剤
JP2005314283A (ja) * 2004-04-28 2005-11-10 Nivea Kao Kk 非水系粉末エアゾール
JP2012158768A (ja) * 2012-05-14 2012-08-23 Kao Corp 香料組成物
JP2018052892A (ja) * 2016-09-30 2018-04-05 アース製薬株式会社 スプレー型芳香剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASAKO AKIYAMA ET AL.: "Determination of Aromatic Compounds in Exhalated from Human Skin by Solid-Phase Micro Extraction and GC/MS with Thermo Desorption System", BUNSEKI KAGAKU- THE JAPAN SOCIETY FOR ANALYTICAL CHEMISTRY, vol. 55, no. 10, 2006, pages 787 - 792, XP055655013 *
DENAWAKA CHAMILA J. ET AL.: "Source, impact and removal of malodour from soiled clothing", JOURNAL OF CHROMATOGRAPHY A, vol. 1438, 2016, pages 216 - 225, XP029436201, DOI: 10.1016/j.chroma.2016.02.037 *
PANDEY SUDHIR KUMAR ET AL.: "Human body-odor components and their determination", TRENDS IN ANALYTICAL CHEMISTRY, vol. 30, no. 5, 2011, pages 784 - 796, XP028197962, DOI: 10.1016/j.trac.2010.12.005 *
PREHN-KRISTENSEN ALEXANDER ET AL.: "Induction of Empathy by the Smell of Anxiety", PLOS ONE, vol. 4, no. 6, 24 June 2009 (2009-06-24), pages 1 - 9, XP055655010 *
SINGH PREET BANO ET AL.: "Smelling Anxiety Chemosignals Impairs Clinical Performance of Dental Students", CHEMICAL SENSES, vol. 43, no. 6, 15 May 2018 (2018-05-15) - July 2018 (2018-07-01), pages 411 - 417, XP055655009 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023079982A1 (fr) * 2021-11-05 2023-05-11 株式会社 資生堂 Produit cosmétique de protection solaire

Also Published As

Publication number Publication date
JPWO2019225754A1 (ja) 2021-06-17
CN112135602B (zh) 2023-08-01
TW202002938A (zh) 2020-01-16
JP2024020230A (ja) 2024-02-14
CN112135602A (zh) 2020-12-25

Similar Documents

Publication Publication Date Title
Kanlayavattanakul et al. Body malodours and their topical treatment agents
WO2002053151A1 (fr) Compositions parfumantes
ES2962680T3 (es) Uso de composiciones volátiles para limitar o eliminar la percepción del mal olor de la materia fecal
JP2013521044A (ja) 空気殺菌・悪臭除去配合物
SG175241A1 (en) Fragrance composition having good sleep-inducing effect
JP2024020230A (ja) 不活性化剤
Heuberger et al. The influence of essential oils on human vigilance
JP2001019992A (ja) 高揚剤及び高揚香料組成物
JP2011152234A (ja) 二酸化塩素ガス発生具
Van Toller Invisible wounds: the effects of skin ulcer malodours
JP7485597B2 (ja) 消臭剤及び不活性化剤
US5759521A (en) Method of altering perception of relative space of an area
JPH07171209A (ja) 消臭剤
KR100446114B1 (ko) 소취용 향료 조성물
JP2014111551A (ja) 化粧料組成物
JP2005296169A (ja) 消臭剤組成物
JP6342382B2 (ja) 消臭剤
Knasko Human responses to ambient olfactory stimuli
KR102780042B1 (ko) 신체 유래 이취 제거용 조성물
JPH11221272A (ja) 消臭剤及び消臭剤組成物
JP2010065233A (ja) 精神高揚用香料組成物を製造するための特定の香料成分の使用、及び、香料組成物における精神高揚効果の付与方法
Monazzam et al. Assessment of odor annoying impacts on trade and serving centers close to a vegetable oil manufacturing plant
JP5392551B2 (ja) 新規消臭剤
JP2025123917A (ja) 消臭用香料組成物
JP2001335501A (ja) 消臭飲料水

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19806811

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020520403

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19806811

Country of ref document: EP

Kind code of ref document: A1